Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities

被引：2
|
作者：
Ma, Christopher [1 ]
Choi, May Y. [1 ]
机构：
[1] Mayo Clin, Dept Gastroenterol & Hepatol, Phoenix, AZ 85054 USA
来源：
LANCET GASTROENTEROLOGY & HEPATOLOGY | 2022年 / 7卷 / 02期
关键词：
MAINTENANCE THERAPY; INDUCTION;
D O I：
10.1016/S2468-1253(21)00432-5
中图分类号：
R57 [消化系及腹部疾病];
学科分类号：
摘要：
引用
收藏
页码：110 / 112
页数：3
相关论文
共 50 条
  • [21] Efficacy and Safety of Vedolizumab in Management of Moderate to Severe Ulcerative Colitis: A Systematic Review
    Bhandari, Renu
    Ogeyingbo, Opemipo D.
    Kareem, Roaa
    Gyawali, Mallika
    Venkatesan, Nanditha
    Ahmed, Rowan
    Botleroo, Rinky A.
    Elshaikh, Abeer O.
    CUREUS JOURNAL OF MEDICAL SCIENCE, 2021, 13 (09)
  • [22] AGA Technical Review on the Management of Moderate to Severe Ulcerative Colitis
    Singh, Siddharth
    Allegretti, Jessica R.
    Siddique, Shazia Mehmood
    Terdiman, Jonathan P.
    GASTROENTEROLOGY, 2020, 158 (05) : 1465 - +
  • [23] Evaluating tofacitinib citrate in the treatment of moderate-to-severe active ulcerative colitis: design, development and positioning of therapy
    Tran, Vivy
    Shammas, Rania M.
    Sauk, Jenny S.
    Padua, David
    CLINICAL AND EXPERIMENTAL GASTROENTEROLOGY, 2019, 12 : 179 - 190
  • [24] Systematic review and network meta-analysis of treatment for moderate-to-severe ulcerative colitis
    Trigo-Vicente, Cristina
    Gimeno-Ballester, Vicente
    Garcia-Lopez, Santiago
    Lopez-Del Val, Alejandro
    INTERNATIONAL JOURNAL OF CLINICAL PHARMACY, 2018, 40 (06) : 1411 - 1419
  • [25] Management of Mild-to-Moderate Ulcerative Colitis
    Siegmund, Britta
    DIGESTIVE DISEASES, 2015, 33 : 90 - 94
  • [26] Model-Informed Assessment of Probability of Phase 3 Success for Ritlecitinib in Patients with Moderate-to-Severe Ulcerative Colitis
    Wojciechowski, Jessica
    Mukherjee, Arnab
    Banfield, Christopher
    Nicholas, Timothy
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2024, 116 (03) : 724 - 735
  • [27] Vidofludimus Calcium in Patients With Moderate-to-Severe Ulcerative Colitis: A Randomized, Placebo-Controlled, Phase 2 Trial
    D'Haens, Geert
    Stardelova, Kalina Grivcheva
    Sadiku, Edite
    Kizlova, Natallia
    Skybalo, Syitlana
    Shehovtsova, Yulia
    Abramescu, Mirela
    Vitt, Daniel
    Kohlhof, Hella
    Muehler, Andreas
    CLINICAL AND TRANSLATIONAL GASTROENTEROLOGY, 2025, 16 (03)
  • [28] Developments in the treatment of moderate to severe ulcerative colitis: focus on adalimumab
    Freeman, Hugh J.
    THERAPEUTICS AND CLINICAL RISK MANAGEMENT, 2013, 9 : 451 - 456
  • [29] Clinical Outcomes of Golimumab as First, Second or Third Anti-TNF Agent in Patients with Moderate-to-Severe Ulcerative Colitis
    Taxonera, Carlos
    Rodriguez, Cristina
    Bertoletti, Federico
    Menchen, Luis
    Arribas, Julia
    Sierra, Monica
    Arias, Lara
    Martinez-Montiel, Pilar
    Juan, Alba
    Iglesias, Eva
    Algaba, Alicia
    Mancenido, Noemi
    Rivero, Montserrat
    Barreiro-de Acosta, Manuel
    Lopez-Serrano, Pilar
    Argueelles-Arias, Federico
    Gutierrez, Ana
    Busquets, David
    Gisbert, Javier P.
    Olivares, David
    Calvo, Marta
    Alba, Cristina
    INFLAMMATORY BOWEL DISEASES, 2017, 23 (08) : 394 - 402
  • [30] Vedolizumab for Moderate to Severe Ulcerative Colitis: A Review for Nurse Practitioners
    Norton, Beth-Ann
    Sullivan, Anne
    Senior, Jennifer
    Candela, Ninfa
    Jason, Mary
    Weyant, Katherine
    JNP- THE JOURNAL FOR NURSE PRACTITIONERS, 2022, 18 (04): : 438 - 445
12345